Halozyme Therapeutics, Inc. (HALO) stock
HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)
Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –
Halozyme Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Halozyme Therapeutics's price to book ratio was 80.8× on Nov 11, 2026, against 16.7× a year earlier. Over the last 5 years it ranged from 13.3× to 167.8×, with a median of 27.8×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 80.8× | +65.1 |
| 2025 | Dec 31, 2025 | 15.7× | +2.3 |
| 2024 | Dec 31, 2024 | 13.4× | −6.2 |
| 2023 | Dec 29, 2023 | 19.6× | −59.7 |
| 2022 | Dec 30, 2022 | 79.3× | +59.2 |
| 2021 | Dec 31, 2021 | 20.1× | −38.3 |
| 2020 | Dec 31, 2020 | 58.4× | +47.8 |
| 2019 | Dec 31, 2019 | 10.6× | +1.8 |
| 2018 | Dec 31, 2018 | 8.8× | −31.0 |
| 2017 | Dec 29, 2017 | 39.8× | −72.8 |
| 2016 | Oct 31, 2016 | 112.6× | +42.9 |
| 2015 | Dec 31, 2015 | 69.7× | +39.3 |
| 2014 | Dec 31, 2014 | 30.3× | −88.1 |
| 2013 | Oct 31, 2013 | 118.4× | +103.7 |
| 2012 | Dec 31, 2012 | 14.8× | −21.7 |
| 2011 | Dec 30, 2011 | 36.4× | – |
See a number that looks wrong?